Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib

Documenti analoghi

• Correction to: Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
  di: Tamura, Kazuo, et al.
  Pubblicazione: (2019)
• A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027
  di: Minegishi, Yuji, et al.
  Pubblicazione: (2021)
• Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
  di: Yamamoto, Nobuyuki, et al.
  Pubblicazione: (2019)
• Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations
  di: Tanaka, Kentaro, et al.
  Pubblicazione: (2017)
• Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
  di: Takahashi, Akiko, et al.
  Pubblicazione: (2018)